Will TMVR follow a similarly rapid, explosive adoption and growth trajectory as TAVR? Rather than valve technology and technical feasibility, the prime determinants of TMVR's applicability are likely to be some key differences that set catheter replacement of the mitral valve apart from that of the aortic valve ( Table 1) . Understanding these differences is critical to further development and clinical evaluation of TMVR platforms.
HETEROGENEITY OF MITRAL VALVE DISEASE. Unlike aortic valve interventions in adults, the majority of to a single disease and a consistent lesion: degenerative calcific stenosis. 
